NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Skip to content
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
<< Back
Apr 26, 2022

Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco.

“We look forward to the presentation of these new data evaluating the ability of our non-invasive Percepta Nasal Swab test to accurately assess lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden,” said Giulia C. Kennedy, Ph.D., Veracyte’s chief scientific and chief medical officer.

Following are details of the abstract accepted for a poster presentation at ATS 2022:

Date/Time:

May 16, 9:30-11:00 a.m. Pacific Time

Title:

A Nasal Genomic Classifier for Assessing Risk of Malignancy In Lung Nodules Demonstrates Similar Performance In Patients that Meet Screening Criteria for High Baseline Risk and Those Who Do Not, Poster #217

Presenter:

Carla R. Lamb, M.D., Lahey Hospital & Medical Center

Location:

Room 203-204, South Building, Level 2, Moscone Center

Poster Discussion B30

Percepta Nasal Swab is a first-of-its-kind genomic test developed for use in current and former smokers with lung nodules. The test is designed to help physicians more accurately, quickly and confidently assess lung cancer risk among these individuals so that those whose lung nodules are benign may avoid unnecessary invasive procedures, and patients whose nodules are likely cancerous may proceed to further diagnostic work-up and, if necessary, treatment or surgery per guideline recommendations. The test’s performance in classifying lung cancer risk has previously been validated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.

Veracyte will also host two Learning Theater events at ATS 2022, during which leading physicians will discuss their experiences incorporating novel genomic testing into the diagnosis of interstitial lung disease (ILD) and lung cancer, respectively:

Title:

Integrating novel genomic data to improve ILD diagnostic and prognostic confidence

Presenter:

Lisa H. Lancaster, M.D.

Date/Time:

May 17, 12:30 p.m. Pacific Time

Location:

Mini Theater #2

 

Title:

Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification

Presenters:

David Feller-Kopman, M.D. and Shaheen Islam, M.D.

Date/Time:

May 17, 1:30 p.m. Pacific Time

Location:

Mini Theater #1

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Nasal Swab test. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward looking statement include, among others, that the Percepta Nasal Swab test is designed to help physicians more accurately, quickly and confidently assess lung cancer risk among these individuals so that those whose lung nodules are benign may avoid unnecessary invasive procedures Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 28, 2022, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

Investors:
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.